View Older Stories View More Recent Stories

Jun 28, 2018 08:00AM Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
Jun 26, 2018 08:08AM Actinium Pharma (ATNM) Reports Dosing of 38th Patient and 25% Enrollment in Iomab-B Pivotal SIERRA Trial
Jun 26, 2018 08:00AM Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial
Jun 25, 2018 04:15PM Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 13, 2018 08:00AM Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
May 8, 2018 07:30AM Actinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, Belgium
May 1, 2018 07:30AM Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors
Apr 18, 2018 07:30AM Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D.
Apr 11, 2018 07:30AM Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting
Mar 28, 2018 08:05AM Actinium Pharma (ATNM) Announces Pact with Astellas Leveraging Actinium's AWE Platform Technology
Mar 28, 2018 08:00AM Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
Mar 15, 2018 07:30AM Actinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare Conference
Mar 14, 2018 07:30AM Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
Mar 13, 2018 07:39AM Actinium Pharma (ATNM) Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with R/R AML
Mar 13, 2018 07:30AM Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
Mar 7, 2018 07:30AM Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference
Mar 5, 2018 07:30AM Actinium Announces $15.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering
Feb 28, 2018 07:30AM Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
Feb 27, 2018 07:34AM Actinium Pharma (ATNM) Announces Activation of Sixteenth Clinical Trial Site in Phase 3 SIERRA Trial for Iomab-B
Feb 27, 2018 07:30AM Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B
Feb 26, 2018 09:53AM Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and Amendment to Pricing Terms of its Rights Offering
Feb 22, 2018 07:30AM Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period
Feb 20, 2018 07:30AM Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
Feb 12, 2018 04:27PM Actinium Pharma (ATNM) Reports Submission of IND For Actimab-A in Combination with CLAG-M for Patients with R/R AML
Feb 12, 2018 04:15PM Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
Feb 12, 2018 07:30AM Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record
Feb 8, 2018 08:00AM Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
Feb 7, 2018 09:00AM Actinium Pharmaceuticals Reminds Investors of Record Date for Rights Offering
Feb 6, 2018 07:39AM Actinium Pharma (ATNM) Reports Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
Feb 6, 2018 07:30AM Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
Feb 5, 2018 04:15PM Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
Feb 1, 2018 04:39PM Actinium Pharma (ATNM) Announces Rights Offering
Feb 1, 2018 04:05PM Actinium Pharmaceuticals Announces Rights Offering
Feb 1, 2018 07:30AM Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbus
Jan 25, 2018 08:07AM Actinium Pharma (ATNM) Provides Update and Outlook for 2018
Jan 25, 2018 08:00AM Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018
Jan 8, 2018 07:30AM Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs
Jan 3, 2018 07:30AM Actinium Pharmaceuticals to Present at Biotech Showcase™ 2018 and Participate in Partnering Sessions
Dec 27, 2017 09:02AM Actinium Pharma (ATNM) Reports Update on Pivotal Phase 3 Trial of Iomab-B; 'Independent Data Monitoring Committee Recommends SIERRA Trial Continue'
Dec 27, 2017 09:00AM Actinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
Dec 12, 2017 07:33AM Actinium Pharma (ATNM) Reports Promising Data on Labeling of Daratumumab with Radioisotope Actinium-225
Dec 12, 2017 07:30AM Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting
Dec 11, 2017 04:15PM Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for
Dec 11, 2017 06:33AM Actinium Pharma (ATNM) Posts Positive Phase 2 Trial for Actimab-A in AML at ASH
Dec 11, 2017 06:30AM Actinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual Meeting
Dec 5, 2017 07:32AM Actinium Pharma (ATNM) Announces Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
Dec 5, 2017 07:30AM Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
Nov 29, 2017 07:30AM Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform
Nov 14, 2017 08:00AM Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform
Nov 13, 2017 07:30AM Actinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail Roboz
View More Recent Stories View Older Stories